The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Identifieur interne : 000833 ( Main/Curation ); précédent : 000832; suivant : 000834The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Auteurs : Pál Pacher ; Sándor Bátkai ; George KunosSource :
- Pharmacological reviews [ 0031-6997 ] ; 2006.
Abstract
The recent identification of cannabinoid receptors and their endogenous lipid ligands has triggered an exponential growth of studies exploring the endocannabinoid system and its regulatory functions in health and disease. Such studies have been greatly facilitated by the introduction of selective cannabinoid receptor antagonists and inhibitors of endocannabinoid metabolism and transport, as well as mice deficient in cannabinoid receptors or the endocannabinoid-degrading enzyme fatty acid amidohydrolase. In the past decade, the endocannabinoid system has been implicated in a growing number of physiological functions, both in the central and peripheral nervous systems and in peripheral organs. More importantly, modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathological conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson’s and Huntington’s disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few. An impediment to the development of cannabinoid medications has been the socially unacceptable psychoactive properties of plant-derived or synthetic agonists, mediated by CB1 receptors. However, this problem does not arise when the therapeutic aim is achieved by treatment with a CB1 receptor antagonist, such as in obesity, and may also be absent when the action of endocannabinoids is enhanced indirectly through blocking their metabolism or transport. The use of selective CB2 receptor agonists, which lack psychoactive properties, could represent another promising avenue for certain conditions. The abuse potential of plant-derived cannabinoids may also be limited through the use of preparations with controlled composition and the careful selection of dose and route of administration. The growing number of preclinical studies and clinical trials with compounds that modulate the endocannabinoid system will probably result in novel therapeutic approaches in a number of diseases for which current treatments do not fully address the patients’ need. Here, we provide a comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy.
Url:
DOI: 10.1124/pr.58.3.2
PubMed: 16968947
PubMed Central: 2241751
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000334
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000333
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000352
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000064
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000064
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000064
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :000842
Links to Exploration step
PMC:2241751Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Endocannabinoid System as an Emerging Target of Pharmacotherapy</title>
<author><name sortKey="Pacher, Pal" sort="Pacher, Pal" uniqKey="Pacher P" first="Pál" last="Pacher">Pál Pacher</name>
</author>
<author><name sortKey="Batkai, Sandor" sort="Batkai, Sandor" uniqKey="Batkai S" first="Sándor" last="Bátkai">Sándor Bátkai</name>
</author>
<author><name sortKey="Kunos, George" sort="Kunos, George" uniqKey="Kunos G" first="George" last="Kunos">George Kunos</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">16968947</idno>
<idno type="pmc">2241751</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2241751</idno>
<idno type="RBID">PMC:2241751</idno>
<idno type="doi">10.1124/pr.58.3.2</idno>
<date when="2006">2006</date>
<idno type="wicri:Area/Pmc/Corpus">000334</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000334</idno>
<idno type="wicri:Area/Pmc/Curation">000333</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000333</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000352</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000352</idno>
<idno type="wicri:Area/Ncbi/Merge">000064</idno>
<idno type="wicri:Area/Ncbi/Curation">000064</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000064</idno>
<idno type="wicri:doubleKey">0031-6997:2006:Pacher P:the:endocannabinoid:system</idno>
<idno type="wicri:Area/Main/Merge">000842</idno>
<idno type="wicri:Area/Main/Curation">000833</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The Endocannabinoid System as an Emerging Target of Pharmacotherapy</title>
<author><name sortKey="Pacher, Pal" sort="Pacher, Pal" uniqKey="Pacher P" first="Pál" last="Pacher">Pál Pacher</name>
</author>
<author><name sortKey="Batkai, Sandor" sort="Batkai, Sandor" uniqKey="Batkai S" first="Sándor" last="Bátkai">Sándor Bátkai</name>
</author>
<author><name sortKey="Kunos, George" sort="Kunos, George" uniqKey="Kunos G" first="George" last="Kunos">George Kunos</name>
</author>
</analytic>
<series><title level="j">Pharmacological reviews</title>
<idno type="ISSN">0031-6997</idno>
<idno type="eISSN">1521-0081</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">The recent identification of cannabinoid receptors and their endogenous lipid ligands has triggered an exponential growth of studies exploring the endocannabinoid system and its regulatory functions in health and disease. Such studies have been greatly facilitated by the introduction of selective cannabinoid receptor antagonists and inhibitors of endocannabinoid metabolism and transport, as well as mice deficient in cannabinoid receptors or the endocannabinoid-degrading enzyme fatty acid amidohydrolase. In the past decade, the endocannabinoid system has been implicated in a growing number of physiological functions, both in the central and peripheral nervous systems and in peripheral organs. More importantly, modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathological conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson’s and Huntington’s disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few. An impediment to the development of cannabinoid medications has been the socially unacceptable psychoactive properties of plant-derived or synthetic agonists, mediated by CB<sub>1</sub>
receptors. However, this problem does not arise when the therapeutic aim is achieved by treatment with a CB<sub>1</sub>
receptor antagonist, such as in obesity, and may also be absent when the action of endocannabinoids is enhanced indirectly through blocking their metabolism or transport. The use of selective CB<sub>2</sub>
receptor agonists, which lack psychoactive properties, could represent another promising avenue for certain conditions. The abuse potential of plant-derived cannabinoids may also be limited through the use of preparations with controlled composition and the careful selection of dose and route of administration. The growing number of preclinical studies and clinical trials with compounds that modulate the endocannabinoid system will probably result in novel therapeutic approaches in a number of diseases for which current treatments do not fully address the patients’ need. Here, we provide a comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy.</p>
</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/CobaltMaghrebV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000833 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000833 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Terre |area= CobaltMaghrebV1 |flux= Main |étape= Curation |type= RBID |clé= PMC:2241751 |texte= The Endocannabinoid System as an Emerging Target of Pharmacotherapy }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:16968947" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a CobaltMaghrebV1
![]() | This area was generated with Dilib version V0.6.32. | ![]() |